Literature DB >> 20451421

Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection.

Mototsugu Muramaki1, Hideaki Miyake, Tomoaki Terakawa, Masafumi Kumano, Iori Sakai, Masato Fujisawa.   

Abstract

The objective of this study was to investigate the impact of the expression profile of E-cadherin and N-cadherin in newly diagnosed non-muscle-invasive bladder cancer (NMIBC) on the probability of intravesical recurrence in patients undergoing transurethral resection (TUR). This study included 115 consecutive patients diagnosed as having NMIBC following TUR. Expression levels of E-cadherin and N-cadherin in TUR specimens from these patients were measured by immunohistochemical staining. In this series, intravesical recurrence occurred in 35 of 115 patients (30.4%). Immunohistochemical study showed that positive expression of E-cadherin and N-cadherin were noted in 62 (53.9%) and 48 (41.7%) specimens, respectively. Intravesical recurrence was detected in only 7 of 62 patients (11.3%) with positive E-cadherin expression, while 33 of 48 patients (68.8%) with positive N-cadherin expression developed intravesical recurrence. When patients were divided into 4 groups according to the positivities of E-cadherin and N-cadherin expression, intravesical recurrence was detected in 27 of 30 patients (90.0%) with negative E-cadherin as well as positive N-cadherin expression, and the intravesical recurrence-free survival of this group was significantly poorer than those of the remaining 3 groups. Furthermore, negative E-cadherin as well as positive N-cadherin expression was identified as the most powerful independent predictor for intravesical recurrence following TUR on multivariate analysis. These findings suggest that the loss of E-cadherin and gain of N-cadherin expression in on NMIBC appeared to be significantly associated with postoperative recurrence; therefore, the switch from E-cadherin to N-cadherin expression might be involved in the mechanism underlying intravesical recurrence of on NMIBC. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451421     DOI: 10.1016/j.urolonc.2010.01.005

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  25 in total

1.  Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.

Authors:  Bangmin Han; Di Cui; Yifeng Jing; Yan Hong; Shujie Xia
Journal:  World J Urol       Date:  2014-02       Impact factor: 4.226

2.  WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.

Authors:  Wolfgang Otto; Johannes Breyer; Sonja Herdegen; Fabian Eder; Simone Bertz; Matthias May; Roman Mayr; Eva M Lausenmeyer; Stefan Denzinger; Bas W G van Rhijn; Maximilian Burger; Arndt Hartmann
Journal:  Int Urol Nephrol       Date:  2016-12-29       Impact factor: 2.370

3.  B-cell receptor-associated protein 31 promotes migration and invasion in ovarian cancer cells.

Authors:  Haiyan Liang; Jiqiao Dong; Ziyan Cheng; Qian Li; Dingqing Feng; Bin Ling
Journal:  Exp Ther Med       Date:  2021-06-09       Impact factor: 2.447

4.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Authors:  Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith
Journal:  Cancer       Date:  2014-05-06       Impact factor: 6.860

5.  Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.

Authors:  Bangmin Han; Di Cui; Yifeng Jing; Yan Hong; Shujie Xia
Journal:  World J Urol       Date:  2012-01-12       Impact factor: 4.226

6.  Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.

Authors:  Pi-Che Chen; Ming-Hsuan Tsai; Sidney K H Yip; Yeong-Chin Jou; Chi-Fai Ng; Yanning Chen; Xiaoling Wang; Wei Huang; Chun-Liang Tung; Gary C W Chen; Martin M S Huang; Joanna H M Tong; Eing-Ju Song; De-Ching Chang; Cheng-Da Hsu; Ka-Fai To; Cheng-Huang Shen; Michael W Y Chan
Journal:  BMC Med Genomics       Date:  2011-05-20       Impact factor: 3.063

7.  Dynamic Change in p63 Protein Expression during Implantation of Urothelial Cancer Clusters.

Authors:  Takahiro Yoshida; Hiroaki Okuyama; Masashi Nakayama; Hiroko Endo; Yasuhiko Tomita; Norio Nonomura; Kazuo Nishimura; Masahiro Inoue
Journal:  Neoplasia       Date:  2015-07       Impact factor: 5.715

8.  Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing.

Authors:  Song Wu; Zhao Yang; Rui Ye; Dan An; Chong Li; Yitian Wang; Yongqiang Wang; Yi Huang; Huan Liu; Feida Li; Luyun He; Da Sun; Yuan Yu; Qiaoling Li; Peide Huang; Meng Zhang; Xin Zhao; Tengteng Bi; Xuehan Zhuang; Liyan Zhang; Jingxiao Lu; Xiaojuan Sun; Fangjian Zhou; Chunxiao Liu; Guosheng Yang; Yong Hou; Zusen Fan; Zhiming Cai
Journal:  Oncotarget       Date:  2016-01-19

9.  How Cancer Cells Invade Bladder Epithelium and Form Tumors: The Mouse Bladder Tumor Model as a Model of Tumor Recurrence in Patients.

Authors:  Andreja Erman; Urška Kamenšek; Urška Dragin Jerman; Mojca Pavlin; Maja Čemažar; Peter Veranič; Rok Romih
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

10.  Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells.

Authors:  Ke-Hung Tsui; Shu-Yuan Hsu; Li-Chuan Chung; Yu-Hsiang Lin; Tsui-Hsia Feng; Tzu-Yi Lee; Phei-Lang Chang; Horng-Heng Juang
Journal:  Sci Rep       Date:  2015-08-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.